Crossmark

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

Crossref DOI link: https://doi.org/10.1007/s00415-019-09327-8

Published Online: 2019-04-19

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Kempen, Zoé L. E. https://orcid.org/0000-0001-9557-5381
van Rossum, Johannis A.

Doesburg, Djoeke

Claessen, Iris

de Vries, Annick

ten Brinke, Anja

van Oosten, Bob W.

Rispens, Theo

Killestein, Joep
License Information

Text and Data Mining valid from 2019-04-19
More Information

Article History

Received: 1 March 2019

Revised: 12 April 2019

Accepted: 13 April 2019

First Online: 19 April 2019

Compliance with ethical standards

:

: Z. van Kempen, J. van Rossum, D. Doesburg, A. de Vries, I. Claessen, A. de Vries and B. van Oosten: nothing to report. T. Rispens: has received speaking fees from Pfizer and AbbVie. J. Killestein: has received speaker and consulting fees from Merck-Serono, Biogen Idec, TEVA, Genzyme, Roche and Novartis.

: This article does not contain any studies with human participants or animals performed by any of the authors.